evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

959 questions · 987 findings · 78 reviews · Haematology

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 256 · 25.9%GRADE not reported 64 · 6.5%Very low 207 · 21%Low 247 · 25%Moderate 163 · 16.5%High 50 · 5.1%

Summary of findings: Antithrombin III plus heparin vs heparin

Incidence of hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases

It is very uncertain whether summary of findings: Antithrombin III plus heparin changes incidence of hepatic veno‐occlusive disease ( compared with heparin alone (very low certainty).

1 finding from 1 review

Ursodeoxycholic acid vs placebo or no treatment

Mortality attributable to hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases

It is very uncertain whether summary of findings: Ursodeoxycholic acid changes mortality attributable to hepatic veno‐occlusive disease ( compared with placebo or no treatment (very low certainty).

1 finding from 1 review

Summary of findings: Antithrombin III plus heparin vs heparin

Mortality attributable to hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases

It is very uncertain whether summary of findings: Antithrombin III plus heparin changes mortality attributable to hepatic veno‐occlusive disease ( compared with heparin alone (very low certainty).

1 finding from 1 review

Summary of findings: Antithrombin III plus heparin vs heparin

Frequency of adverse events ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases

It is very uncertain whether summary of findings: Antithrombin III plus heparin changes frequency of adverse events ( compared with heparin alone (very low certainty).

1 finding from 1 review

Heparin vs low molecular weight heparin

Incidence of hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases

It is very uncertain whether summary of findings: Heparin changes incidence of hepatic veno‐occlusive disease ( compared with low molecular weight heparin (very low certainty).

1 finding from 1 review

Heparin vs low molecular weight heparin

Mortality attributable to hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases

It is very uncertain whether summary of findings: Heparin changes mortality attributable to hepatic veno‐occlusive disease ( compared with low molecular weight heparin (very low certainty).

1 finding from 1 review

Heparin vs low molecular weight heparin

Frequency of adverse events ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases

It is very uncertain whether summary of findings: Heparin changes frequency of adverse events ( compared with low molecular weight heparin (very low certainty).

1 finding from 1 review

Heparin vs prostaglandin E1

Incidence of hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases

It is very uncertain whether summary of findings: Heparin changes incidence of hepatic veno‐occlusive disease ( compared with prostaglandin E1 (very low certainty).

1 finding from 1 review